Poly Medicure Ltd is Rated Hold by MarketsMOJO

25 minutes ago
share
Share Via
Poly Medicure Ltd is rated 'Hold' by MarketsMojo, with this rating last updated on 10 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Poly Medicure Ltd is Rated Hold by MarketsMOJO

Understanding the Current Rating

The 'Hold' rating assigned to Poly Medicure Ltd indicates a balanced outlook for investors. It suggests that while the stock may not be an immediate buy, it is not recommended for sale either. This rating reflects a nuanced assessment of the company’s quality, valuation, financial trends, and technical indicators, which together shape the investment case.

Quality Assessment

As of 13 September 2026, Poly Medicure Ltd holds a 'good' quality grade. The company is net-debt free, which is a positive sign of financial health and prudent management. However, its operating profit growth over the past five years has been moderate, with a compound annual growth rate of 13.82%. This indicates steady but unspectacular expansion in core earnings. Additionally, the company has reported negative results for the last three consecutive quarters, signalling some operational challenges that investors should monitor closely.

Valuation Considerations

The valuation grade for Poly Medicure Ltd is classified as 'very expensive'. Currently, the stock trades at a price-to-book value of 5.7, which is high relative to typical benchmarks. Despite this, the stock’s valuation remains in line with its peers’ historical averages, suggesting that the premium price reflects market expectations of the company’s sector position and growth potential. The return on equity (ROE) stands at 10.5%, which, while respectable, does not fully justify the elevated valuation in the eyes of some investors.

Financial Trend Analysis

The financial trend for Poly Medicure Ltd is rated 'negative' as of today. The company’s interest expenses have increased significantly, with a 44.57% rise in the latest six months to ₹12.91 crores. Return on capital employed (ROCE) has declined to a low of 13.08% in the half-year period, and cash and cash equivalents have dropped to ₹87.87 crores, the lowest level recorded recently. These factors point to some strain on the company’s financial performance and liquidity, which may weigh on investor sentiment.

Technical Outlook

From a technical perspective, the stock is mildly bullish. Recent price movements show resilience, with a 3-month return of +17.50% and a 6-month gain of +30.50%. However, the stock has underperformed the broader market over the past year, delivering a -13.04% return compared to the BSE500’s -1.42%. This mixed technical picture suggests that while there is some upward momentum, caution remains warranted given the stock’s volatility and recent negative quarterly results.

Current Market Position and Sector Context

Poly Medicure Ltd is a significant player in the healthcare services sector, with a market capitalisation of approximately ₹17,743 crores. It is the second largest company in its sector, representing 11.34% of the entire industry by market cap. Its annual sales of ₹1,997.43 crores account for 15.78% of the sector’s total, underscoring its importance within the healthcare services landscape. Institutional investors hold a substantial 21.64% stake, reflecting confidence from well-resourced market participants who typically conduct thorough fundamental analysis.

Stock Performance Overview

As of 13 September 2026, Poly Medicure Ltd’s stock performance has been mixed. The stock declined by 0.57% on the most recent trading day and has experienced a 6.91% drop over the past month. However, it has shown strength over the medium term, with gains of 17.50% over three months and 30.50% over six months. Year-to-date, the stock is down 2.15%, and over the last year, it has fallen by 13.04%. These figures highlight the stock’s volatility and the challenges it faces in maintaining consistent upward momentum.

Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.

  • - Strong fundamental track record
  • - Consistent growth trajectory
  • - Reliable price strength

Count on This Pick →

What the Hold Rating Means for Investors

For investors, the 'Hold' rating on Poly Medicure Ltd suggests a cautious approach. The company’s solid quality and sector standing are tempered by its expensive valuation and recent financial headwinds. Investors should weigh the company’s net-debt-free status and institutional backing against the negative financial trends and recent quarterly losses. The mildly bullish technical signals offer some optimism, but the stock’s underperformance relative to the market over the past year advises prudence.

Investment Considerations

Investors considering Poly Medicure Ltd should monitor upcoming quarterly results closely to assess whether the company can reverse its recent negative earnings trend. The elevated valuation means that expectations are high, and any further deterioration in financial performance could pressure the stock price. Conversely, sustained improvement in operating profit growth and cash reserves could support a more positive outlook in the future.

Summary

In summary, Poly Medicure Ltd’s current 'Hold' rating reflects a balanced view of its strengths and challenges. The company’s good quality, net-debt-free position, and sector prominence are offset by a very expensive valuation and negative financial trends. The mildly bullish technical outlook provides some support, but investors should remain vigilant and consider the stock’s recent underperformance and earnings volatility when making portfolio decisions.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
Ugar Sugar Works Ltd. is Rated Sell
24 minutes ago
share
Share Via
S Chand & Company Ltd is Rated Sell
24 minutes ago
share
Share Via
Alicon Castalloy Ltd is Rated Sell
24 minutes ago
share
Share Via
Stovec Industries Ltd is Rated Sell
24 minutes ago
share
Share Via
Oswal Green Tech Ltd is Rated Strong Sell
24 minutes ago
share
Share Via